Association Between Polymorphism of Tumor Necrosis Factor-α Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B
- 15 October 2009
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 55 (7) , 2043-2048
Abstract
TNF-α promoter polymorphism is known to play an important role in the immunopathogenesis of infection of hepatitis B virus. We investigated whether polymorphisms of TNF-α promoter at position −308 or −238 had associations with the response to lamivudine treatment. A total of 89 healthy subjects (control group) and 225 patients with chronic hepatitis B treated with lamivudine were included in this study. Polymorphisms of TNF-α promoter at position −308 and −238 were analyzed by polymerase chain reaction. Recruited patients were classified according to the outcome of lamivudine treatment into the responder (103 patients) or non-responder (122 patients) group. The numbers of A allelic polymorphism of TNF-α promoter at position −238 were four (2.2%) in the control, five (2.4%) in the responder and 19 (7.8%) in the non-responder group. The A allele was noted significantly more frequently in the responder than non-responder group (P = 0.012). At position −308, a significant difference was observed between the control group (14; 7.9%) and total chronic hepatitis B patients (15; 3.3%) (P = 0.015). Our study demonstrated that the non-response to lamivudine treatment in patients with chronic hepatitis B might be related to the A allelic polymorphism of TNF-α promoter at position −238.Keywords
This publication has 29 references indexed in Scilit:
- Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in KoreaJournal of Medical Virology, 2006
- Association between vitamin D receptor, CCR5, TNF-α and TNF-β gene polymorphisms and HBV infection and severity of liver diseaseJournal of Hepatology, 2006
- Association between tumour necrosis factor gene polymorphisms and the clinical types of patients with chronic hepatitis B virus infectionClinical Microbiology and Infection, 2005
- FUNCTIONAL ANALYSIS OF LINKER-SCAN MUTANTS SPANNING THE −376, −308, −244, AND −238 POLYMORPHIC SITES OF THE TNF-α PROMOTERCytokine, 2001
- Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.Journal of Clinical Investigation, 1998
- HLA-DRB1*1301 AND *1302 protect against chronic hepatitis BJournal of Hepatology, 1997
- Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T LymphocytesImmunity, 1996
- Hepatitis B Virus ImmunopathogenesisAnnual Review of Immunology, 1995
- A case for cytokines as effector molecules in the resolution of virus infectionImmunology Today, 1993
- An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.Journal of Experimental Medicine, 1993